Scalper1 News
Israeli specialty-drug giant Teva Pharmaceutical Industries (TEVA) said Tuesday that it’s agreed to buy privately held Labrys Biologics, gaining a migraine drug that it expects to be a blockbuster. Teva agreed to pay $200 million upfront for Labrys, plus up to $625 million in milestone payments as Labrys’ drug LBR-101 works its way through the approval process Scalper1 News
Scalper1 News